Risedronate/zinc-hydroxyapatite based nanomedicine for osteoporosis

Khajuria, Deepak Kumar; Disha, Choudhary; Vasireddi, Ramakrishna; Razdan, Rema; Mahapatra, D. Roy

doi:10.1016/j.msec.2016.02.062

Cited by 53 publications

(26 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Khajuria et al [32] developed a nano-drug for osteoporosis that includes risedronate loaded onto zinc hydroxyapatite nanoparticles by an absorption method. Risedronate has a high affinity for bone and is used as the targeting moiety.…”

Section: Nanotechnology For Osteoporosismentioning

confidence: 99%

Nanotechnology towards prevention of anaemia and osteoporosis: from concept to market

Shukla

Dasgupta

Ranjan

et al. 2017

Biotechnology & Biotechnological Equipment

View full text Add to dashboard Cite

The application of nanotechnology in medicine, diagnostics, therapeutics, drug delivery, etc. in order to overcome the limitations faced by these fields has already been established. Anaemia and osteoporosis are two of the most widely prevalent iron and calcium deficiency diseases among women. Conventional drugs for both have their inherent limitations which can be overcome by nanotechnology. Nanonization of drugs has been established as a very efficient way to enhance the bioavailability and absorption of the drug in the gastrointestinal tract. In addition to this, encapsulation of drugs in solid lipid nanoparticles is also employed to increase the stability of the drug in the gastrointestinal tract and to facilitate its controlled release. Nanotechnology is also applied in bone tissue engineering to prepare bone grafts for bone injury. Nanotechnology-based bone grafts have shown to possess enhanced mechanical properties and better biocompatibility and osteoconduction than the conventional bone grafts. This review article highlights the research trends and challenges of nanotechnology based drugs to combat iron deficiency anaemia and osteoporosis. This review outlines the recent research trends in nano-drugs and touches on issues concerning the market, industries and patents pertaining to drugs for anaemia and osteoporosis. To provide the safety and risk factors of nanomaterials, we have briefly highlighted the toxicological aspects of nanomaterials used in drugs.

show abstract

Section: Nanotechnology For Osteoporosismentioning

confidence: 99%

Nanotechnology towards prevention of anaemia and osteoporosis: from concept to market

Shukla

Dasgupta

Ranjan

et al. 2017

Biotechnology & Biotechnological Equipment

View full text Add to dashboard Cite

show abstract

“…Therefore, in future, both effective drugs and efficient drug-delivery systems are needed for preventing OP before fractures occur. 55,56 To facilitate OP treatment, a bone-resorption areatargeting delivery system could be a good tool. For targeted delivery, selecting a good molecule to guide the drug carrier toward bone-resorption areas is a key issue.…”

Section: Discussionmentioning

confidence: 99%

A bone-resorption surface-targeting nanoparticle to deliver anti-miR214 for osteoporosis therapy

Cai

Yang

Zhang

et al. 2017

IJN

View full text Add to dashboard Cite

With increasing fracture risks due to fragility, osteoporosis is a global health problem threatening postmenopausal women. In these patients, osteoclasts play leading roles in bone loss and fracture. How to inhibit osteoclast activity is the key issue for osteoporosis treatment. In recent years, miRNA-based gene therapy through gene regulation has been considered a potential therapeutic method. However, in light of the side effects, the use of therapeutic miRNAs in osteoporosis treatment is still limited by the lack of tissue/cell-specific delivery systems. Here, we developed polyurethane (PU) nanomicelles modified by the acidic peptide Asp 8 . Our data showed that without overt toxicity or eliciting an immune response, this delivery system encapsulated and selectively deliver miRNAs to OSCAR + osteoclasts at bone-resorption surface in vivo. With the Asp 8 -PU delivery system, anti-miR214 was delivered to osteoclasts, and bone microarchitecture and bone mass were improved in ovariectomized osteoporosis mice. Therefore, Asp 8 -PU could be a useful bone-resorption surface-targeting delivery system for treatment of osteoclast-induced bone diseases and aging-related osteoporosis.

show abstract

“…Despite their therapeutic effects, bisphosphonates are currently used in various studies as suitable targeting agents in radiotherapy [4,5] . Previous studies from our laboratory and others have shown that bisphosphonates could be useful as drug bone targeted carriers for delivering various nanoparticle-based therapeutic interventions to bone tissues for skeletal-related diseases [6][7][8][9][10] . This approach prevents adverse effects such as toxicity due to non-specific tissue interactions, larger medicine dosages, higher costs, and even likely poor patient compliance towards therapy.…”

Section: Research Papermentioning

confidence: 99%

Sensitive and Rapid RP-HPLC Quantification of Zoledronic Acid in a Hydroxyapatite-based Nanoparticles

Khajuria¹,

Razdan²

2017

pharmaceutical-sciences

Self Cite

View full text Add to dashboard Cite

The aim of this study was to develop and validate a rapid and sensitive reverse-phase high performance liquid chromatography method for the quantitative determination of zoledronic acid in nanoparticles. The mobile phase was a mixture of methanol (30%) and 7 mM tetra butyl ammonium hydrogen sulphate, 2 mM di-sodium hydrogen orthophosphate and sulphate and 8 mM di-potassium hydrogen orthophosphate (70%), pH adjusted to 3 with trifluoroacetic acid. C18 column was used as a stationary phase. The flow rate was maintained at 1 ml/min. The detection of the constituents was done at 215 nm using an ultraviolet detector. Method validation was executed according to the International Conference on Harmonisation guidelines. The retention time of zoledronic acid was 3.27±0.03 min (n=6). The assay was linear over the concentration range of 200-800 μg/ml. The proposed method was sensitive with the limit of detection and limit of quantification values equal to 200 and 800 µg/ml, respectively. The method was accurate with percent mean recovery from 99.01±1.31 to 100.80±0.094% and precise as percent relative standard deviation values were less than 1%. The method was successfully applied for the estimation of zoledronic acid loading efficiency on hydroxyapatite nanoparticles and in vitro zoledronic acid release profile analysis in hydroxyapatite-based nanoparticles.

show abstract

Risedronate/zinc-hydroxyapatite based nanomedicine for osteoporosis

Cited by 53 publications

References 31 publications

Nanotechnology towards prevention of anaemia and osteoporosis: from concept to market

Nanotechnology towards prevention of anaemia and osteoporosis: from concept to market

A bone-resorption surface-targeting nanoparticle to deliver anti-miR214 for osteoporosis therapy

Sensitive and Rapid RP-HPLC Quantification of Zoledronic Acid in a Hydroxyapatite-based Nanoparticles

Contact Info

Product

Resources

About